Article By:
BioMedReports
Wednesday, March 4, 2015 5:15 AM EDT
ADMP announced the results of its pharmacokinetic (PK) study for its dry powder inhaler product, APC-5000. BOTA announced it has commenced dosing of patients in its Phase 2b SPIRITUS trial of vapendavir.